When Lisa Newell was pregnant with her third son, a complication with her placenta landed her on bedrest for a month. After she gave birth, doctors assumed that the pain she felt in her sternum and ribs was related to her lying in bed for the last month of her pregnancy. Massage made the pain worse. A chiropractor recommended X-rays, which led to an MRI, which led to an unexpected diagnosis five months after her child was born: Newell, now a mom of three, had stage 4 breast cancer. “A lot of people asked me how I managed with three boys at home,” says Newell, whose other sons were 2 and 10 at the time. “Honestly, I don’t know what I would have done without them. They kept me grounded and focused on what I could do instead of what I couldn’t do.” That was 2006.
Dr. Fred Appelbaum, former long-time president of Seattle Cancer Care Alliance, has been designated one of 15 “Giants of Cancer Care” for his contributions to leukemia research. The award, announced by digital publication OncLive, recognizes top researchers who have helped advance the understanding and treatment of cancer.
For Dr. Renato Martins, the theme that Seattle Cancer Care Alliance chose for the American Society of Clinical Oncology's annual meeting -- "tomorrow's treatments today” -- is more than just a catchy slogan. It’s his life’s work, illustrated by a clinical trial that was instrumental in changing the way that lung cancer patients are treated. Dr. Martins, medical director for thoracic/head and neck oncology and outpatient general oncology/hematology at Seattle Cancer Care Alliance, was one of the principal investigators in the Keynote 21 trial that led to FDA approval of a combined regimen of chemotherapy and immunotherapy for adenocarcinoma of the lung.
April is National Cancer Control Month, a time set aside to highlight the prevention and early detection of cancer. Last year, more than 1.7 million new cases of cancer were diagnosed in the U.S., and more than 609,000 people died of cancer-related causes, according to estimates from the National Cancer Institute. At the same time, the overall death rate from cancer has been decreasing. Declines in death rates for many cancers has led to an increase in the number of cancer survivors, who often have lasting complications from their treatment.
The Atlantic has convened a handful of evenings across the country as part of
its Cancer and the Community series in which researchers, doctors and patient advocates discuss advances in cancer care. On Tuesday, it was Seattle’s turn, with the spotlight on the care and research being carried out at Seattle Cancer Care Alliance (SCCA) and the Fred Hutchinson Cancer Research Institute.